Literature DB >> 10816448

Protection against virulent Mycobacterium avium infection following DNA vaccination with the 35-kilodalton antigen is accompanied by induction of gamma interferon-secreting CD4(+) T cells.

E Martin1, A T Kamath, J A Triccas, W J Britton.   

Abstract

Mycobacterium avium is an opportunistic pathogen that primarily infects immunocompromised individuals, although the frequency of M. avium infection is also increasing in the immunocompetent population. The antigen repertoire of M. avium varies from that of Mycobacterium tuberculosis, with the immunodominant 35-kDa protein being present in M. avium and Mycobacterium leprae but not in members of the M. tuberculosis complex. Here we show that a DNA vector encoding this M. avium 35-kDa antigen (DNA-35) induces protective immunity against virulent M. avium infection, and this protective effect persists over 14 weeks of infection. In C57BL/6 mice, DNA vaccines expressing the 35-kDa protein as a cytoplasmic or secreted protein, both induced strong T-cell gamma interferon (IFN-gamma) and humoral immune responses. Furthermore, the antibody response was to conformational determinants, confirming that the vector-encoded protein had adopted the native conformation. DNA-35 immunization resulted in an increased activated/memory CD4(+) T-cell response, with an accumulation of CD4(+) CD44(hi) CD45RB(lo) T cells and an increase in antigen-specific IFN-gamma production. The protective effect of the DNA-35 vectors against M. avium infection was comparable to that of vaccination with Mycobacterium bovis BCG and significantly greater than that for previous treated infection with M. avium. These results illustrate the importance of the 35-kDa protein in the protective response to M. avium infection and indicate that DNA vaccination successfully promotes a sustained level of protection during chronic M. avium infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10816448      PMCID: PMC97536          DOI: 10.1128/IAI.68.6.3090-3096.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  36 in total

Review 1.  Modern vaccines. Mycobacterial diseases.

Authors:  P E Fine; L C Rodrigues
Journal:  Lancet       Date:  1990-04-28       Impact factor: 79.321

2.  T-cell immune responses in Mycobacterium avium-infected mice.

Authors:  R D Hubbard; C M Flory; F M Collins
Journal:  Infect Immun       Date:  1992-01       Impact factor: 3.441

3.  Identification of an immunostimulating protein from Mycobacterium leprae.

Authors:  N Mohagheghpour; M W Munn; R H Gelber; E G Engleman
Journal:  Infect Immun       Date:  1990-03       Impact factor: 3.441

4.  The major native proteins of the leprosy bacillus.

Authors:  S W Hunter; B Rivoire; V Mehra; B R Bloom; P J Brennan
Journal:  J Biol Chem       Date:  1990-08-25       Impact factor: 5.157

5.  Induction and expression of protective T cells during Mycobacterium avium infections in mice.

Authors:  R Appelberg; J Pedrosa
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

6.  Mycobacterium avium complex disease in patients with AIDS: seroreactivity to native and recombinant mycobacterial antigens.

Authors:  S L Morris; L Bermudez; S D Chaparas
Journal:  J Clin Microbiol       Date:  1991-12       Impact factor: 5.948

7.  Survival of patients with acquired immune deficiency syndrome and disseminated Mycobacterium avium complex infection with and without antimycobacterial chemotherapy.

Authors:  C R Horsburgh; J A Havlik; D A Ellis; E Kennedy; S A Fann; R E Dubois; S E Thompson
Journal:  Am Rev Respir Dis       Date:  1991-09

Review 8.  Mycobacterial disease, immunosuppression, and acquired immunodeficiency syndrome.

Authors:  F M Collins
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

Review 9.  T cell response to Mycobacterium tuberculosis.

Authors:  I M Orme; P Andersen; W H Boom
Journal:  J Infect Dis       Date:  1993-06       Impact factor: 5.226

10.  An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection.

Authors:  J L Flynn; J Chan; K J Triebold; D K Dalton; T A Stewart; B R Bloom
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

View more
  10 in total

1.  Comparative protective effects of recombinant DNA and Mycobacterium bovis bacille Calmette-Guérin vaccines against M. avium infection.

Authors:  E Martin; J A Triccas; A T Kamath; N Winter; W J Britton
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

Review 2.  On the use of DNA vaccines for the prophylaxis of mycobacterial diseases.

Authors:  Kris Huygen
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

3.  Vaccine strategies against cystic fibrosis pathogens.

Authors:  Vincent Le Moigne; Jean-Louis Gaillard; Jean-Louis Herrmann
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

4.  Cellular immune responses to 35 kDa recombinant antigen of Mycobacterium avium paratuberculosis.

Authors:  S H Basagoudanavar; P P Goswami; V Tiwari
Journal:  Vet Res Commun       Date:  2006-05       Impact factor: 2.459

5.  Coexpression of PPE 34.9 Antigen of Mycobacterium avium subsp. Paratuberculosis with Murine Interferon Gamma in HeLa Cell Line and Study of Their Immunogenicity in Murine Model.

Authors:  Rajib Deb; P P Goswami
Journal:  Biotechnol Res Int       Date:  2011-02-10

6.  Heterologous expression of a gene encoding a 35 kDa protein of Mycobacterium avium paratuberculosis in Escherichia coli.

Authors:  S H Basagoudanavar; P P Goswami; V Tiwari; A K Pandey; N Singh
Journal:  Vet Res Commun       Date:  2004-04       Impact factor: 2.459

7.  Gamma interferon responses induced by a panel of recombinant and purified mycobacterial antigens in healthy, non-mycobacterium bovis BCG-vaccinated Malawian young adults.

Authors:  Gillian F Black; Rosemary E Weir; Steven D Chaguluka; David Warndorff; Amelia C Crampin; Lorren Mwaungulu; Lifted Sichali; Sian Floyd; Lyn Bliss; Elizabeth Jarman; Linda Donovan; Peter Andersen; Warwick Britton; Glyn Hewinson; Kris Huygen; Jens Paulsen; Mahavir Singh; Ross Prestidge; Paul E M Fine; Hazel M Dockrell
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

8.  The combination of plasmid interleukin-12 with a single DNA vaccine is more effective than Mycobacterium bovis (bacille Calmette-Guèrin) in protecting against systemic Mycobacterim avium infection.

Authors:  Ela Martin; Arun T Kamath; Helen Briscoe; Warwick J Britton
Journal:  Immunology       Date:  2003-06       Impact factor: 7.397

9.  Disseminated disease severity as a measure of virulence of Mycobacterium tuberculosis in the guinea pig model.

Authors:  Gopinath S Palanisamy; Erin E Smith; Crystal A Shanley; Diane J Ordway; Ian M Orme; Randall J Basaraba
Journal:  Tuberculosis (Edinb)       Date:  2008-03-05       Impact factor: 3.131

10.  Subunit vaccine protects against a clinical isolate of Mycobacterium avium in wild type and immunocompromised mouse models.

Authors:  Sasha E Larsen; Valerie A Reese; Tiffany Pecor; Bryan J Berube; Sarah K Cooper; Guy Brewer; Diane Ordway; Marcela Henao-Tamayo; Brendan K Podell; Susan L Baldwin; Rhea N Coler
Journal:  Sci Rep       Date:  2021-04-27       Impact factor: 4.996

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.